title: Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
authors: Sophie
authors: S
authors: Roca
authors: Amandine
authors: A
authors: Quivy
authors: Marine
authors: M
authors: Gross-Goupil
authors: Jean-Christophe
authors: JC
authors: Bernhard
authors: Henri
authors: H
authors: De Clermont
authors: Alain
authors: A
authors: Ravaud
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary; D000068338:Everolimus; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011758:Pyrroles / Q000008:administration & dosage; D015363:Quinolones / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077210:Sunitinib; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: C500007:4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D007211:Indoles; D011758:Pyrroles; D015363:Quinolones; D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases; D000077210:Sunitinib; D020123:Sirolimus